OPEN

# Laparoscopic Versus Abdominal Radical Hysterectomy for Cervical Cancer

A Meta-analysis of Randomized Controlled Trials

Fuyun Zhang, MD and Xiaomei Song, MD

**Background:** Laparoscopic radical hysterectomy (LRH) and open abdominal radical hysterectomy (ARH) have been used for cervical cancer treatment. We aimed to perform a meta-analysis to compare the efficacy and safety of LRH and ARH in the treatment of cervical cancer to provide reliable evidence to the clinical cervical cancer treatment.

**Methods:** Two investigators independently searched PubMed and other databases for randomized controlled trials (RCTs) comparing LRH and ARH for cervical cancer treatment up to May 31, 2022. The risk of bias assessment tool recommended by Cochrane library was used for quality assessment. RevMan 5.3 software was used for meta-analysis.

**Results:** Fourteen RCTs with a total of 1700 patients with cervical cancer were finally included. Meta-analyses indicated that compared with ARH, LRH reduced the intraoperative blood loss (mean difference [MD] = -58.08; 95% CI, -70.91, -45.24), the time to first passage of flatus (MD = -14.50; 95% CI, -16.55, -12.44) (all P < 0.05), and increase the number of lymph nodes removed (MD = 3.47; 95% CI, 0.51, 6.43; P = 0.02). There were no significant differences in the duration of surgery (MD = 27.62; 95% CI, -6.26, 61.49), intraoperative complications (odd ratio [OR] = 1.10; 95% CI, 0.33, 1.86), relapse rate (OR = 1.45; 95% CI, 0.56, 3.74), and survival rate (OR = 0.75; 95% CI, 0.52, 1.08) between LRH group and ARH group (all P > 0.05).

**Conclusions:** LRH has more advantages over ARH in the treatment of cervical cancer. Still, the long-term effects and safety of LRH and ARH need more high-quality, large-sample RCTs to be further verified.

**Key Words:** laparoscopic, abdominal, radical hysterectomy, cervical cancer, treatment, care

(Am J Clin Oncol 2022;45:465-474)

F.Z. designed research; F.Z. and X.S. conducted research; F.Z. and X.S. analyzed data; F.Z. and X.S. wrote the first draft of manuscript; F.Z. and X.S. had primary responsibility for final content.

Correspondence: Fuyun Zhang, Department of Gynecology, Pingxiang People's Hospital, Fuyun Zhang, No. 8, Wugong Shanzhong Avenue, Anyuan District, Pingxiang, Jiangxi, China. E-mail: fuyunzhan0608@yeah.net.

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.amjclinicaloncology.com.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. ISSN: 0277-3732/22/4511-0465

DOI: 10.1097/COC.000000000000939

# BACKGROUND

Cervical cancer is one of the most common malignant tumors that seriously threaten women's health, and its incidence ranks third among female malignant tumors in the world, second only to breast cancer and colorectal cancer.<sup>1,2</sup> There are about 500,000 new cases of cervical cancer every year in the world, 85% of which are in developing countries, and about 250,000 people die of cervical cancer each year.<sup>3,4</sup> In China, 140,000 new cases are discovered every year, accounting for about one third of the global patients with cervical cancer, and about 50,000 patients die of cervical cancer of cervical cancer every year.<sup>5,6</sup> In recent years, the incidence of cervical cancer has a younger trend.<sup>7,8</sup> Therefore, the treatment and care of cervical cancer is of great significance to the prognosis of patients.

Radical hysterectomy and lymph node dissection are the surgical methods recommended by the International Federation of Obstetrics and Gynaecology (FIGO) for the treatment of early-stage cervical cancer.9 Since the first successful laparoscopic pelvic lymph node dissection for cervical cancer in 1989, minimally invasive techniques have developed rapidly. In 1991, laparoscopy was first used for pelvic lymph node dissection combined with vaginal hysterectomy in the treatment of early cervical cancer. Laparoscopy has been used for total hysterectomy and pelvic lymph node dissection in the treatment of cervical cancer. Since then, many studies<sup>10-12</sup> have shown that laparoscopic surgery has the advantages of less trauma, faster recovery, and less pain for patients after surgery, which has been valued by the majority of obstetrics and gynecologists. In recent years, many researchers have conducted many studies on the clinical efficacy and safety of laparoscopic surgery for cervical cancer. However, because of the small number of independent research samples and uneven research quality limits the results promotion. So far, no large-sample, multicenter clinical trials have been reported. To this end, we aimed to conduct a meta-analysis to compare the efficacy and safety of laparoscopic radical hysterectomy (LRH) and open abdominal radical hysterectomy (ARH) in the treatment of cervical cancer to provide a reliable basis for the selection of clinical surgical methods for cervical cancer treatment.

# METHODS

This meta-analysis and systematic review was conducted in comply with the statement of preferred reporting items for systematic reviews and meta-analyses<sup>13</sup> (Supplemental Digital Content 1, http://links.lww.com/AJCO/A427 and Supplemental Digital Content 2, http://links.lww.com/AJCO/A428).

## Search Strategy

The 2 authors independently searched PubMed, Web of Science, EMbase, Cochrane Library, China Biomedical Database,

From the Department of Gynaecology, Pingxiang People's Hospital, Pingxiang, Jiangxi, China.

In this study, all methods were performed in accordance with the relevant guidelines and regulations. Ethics approval and consent to participate is not necessary, as our study is a meta-analysis and systematic review.

The authors declare no conflicts of interest.

L

81

I

Chinese National Knowledge Infrastructure (CNKI), Wanfang, and Weipu databases for randomized controlled trials (RCTs) on the efficacy and safety of LRH and ARH for cervical cancer treatment. The retrieval time limit is from the establishment of the database to May 31, 2022. The language was limited to Chinese or English. The search terms used were as following: ("cervical cancer" OR "cervical carcinoma" OR "uterine cervical neoplasms" OR "invasive carcinoma of cervix uteri") AND ("laparoscopy" OR "laparotomy" OR "surgery" OR "abdominal" OR "open").

# Inclusion and Exclusion Criteria

The inclusion criteria for this meta-analysis were as follows: (1) the type of study was a RCT, the language was limited to Chinese and English, (2) the patients were clinically diagnosed with cervical cancer confirmed by pathology and underwent radical hysterectomy (3) LRH was used for the intervention measures in the experimental group, and ARH was used for the intervention measures in the control group, (4) The article reported relevant outcome indicators, such as operation time, intraoperative blood loss, number of lymph node biopsies, recurrence rate, and survival rate. The exclusion criteria for this meta-analysis were as follows: (1) review, case, and basic experimental studies; (2) duplicate published literature reports; (3) research reports for which data could not be extracted.

# Quality Assessment

The RCTs included in this study were assessed using the risk of bias assessment tool for RCTs recommended by Cochrane library.<sup>14</sup> The evaluated items in this tool include (1) the method of generating random sequences; (2) whether the allocation scheme is hidden; (3)whether the personnel is blinded; (4) whether the outcome assessment is blinded; (5) whether the outcome data is complete; (6) whether the results are selectively reported; and (7) whether there is any other bias. For each study result, a choice was made on the above 7 items, including "Yes" (low bias), "No" (high bias), and "Unclear" (lack of relevant information or uncertain bias).

# Literature Screening and Data Extraction

In this meta-analysis, 2 reviewers independently screened the literature and extracted data and cross-checked them. In case of disagreement, a third party was consulted to assist in judgment, and the first original authors would be contacted as much as possible to supplement the lack of data. We extracted the following data: basic information of included studies, including research title, first author, publication journal and time, etc.; basic characteristics of research subjects, including age, number of cases, FIGO stage; Key elements of study design type, and quality assessment; relevant outcome data.

# **Statistical Analysis**

This study used RevMan 5.3 software for meta-analysis. For enumeration data, odd ratio (OR) and its 95% confidence interval (CI) were used as effect size. For measurement data, mean difference (MD) and its 95% CI were used as effect size. The  $\chi^2$  test was used to analyze the heterogeneity between the results of the studies. If there was no statistical heterogeneity among the results of each study (P > 0.10,  $I^2 \leq 50\%$ ), a fixedeffects model was used for meta-analysis; otherwise, a randomeffects model was used for meta-analysis. Publication bias was evaluated by the demonstration of funnel plots, and asymmetry was assessed by means of the Egger regression test. P < 0.05indicated that the difference between groups was statistically significant.

TABLE 1. The	Characteristic	cs of Inclu	uded Ra	TABLE 1. The Characteristics of Included Randomized Controlled Trials	led Trials					
		Sampl	Sample Size	Age (y)	(y)	Pathological Type (Squamous Cell Carcinoma/Other, Case)	uamous Cell , Case)	Clinical Stage (Ia/Ib/IIa/IIb/ III, Case)	o/IIa/IIb/ III, Case)	
Study	Country	LRH	ARH	LRH	ARH	LRH	ARH	LRH	ARH	Outcomes
Campos et al <sup>18</sup>	Portugal	14	19	56 (36-69)	(69)	27/5		0/0/0/12/12	15/17	03
Campos et al <sup>17</sup>	Portugal	16	14	56 (36-69)	(69)	NA	NA	0/0/0/0/0	30/0	03
$Dai^{2\hat{1}}$	China	20	20	$60.06 \pm 9.28$	$61.22 \pm 10.08$	NA	NA	0/0/0/111	0/0/0/10/10	1078
Dong <sup>25</sup>	China	40	40	$60.9 \pm 7.1$	$58.8 \pm 9.4$	32/8	35/5	NA	NA	000
$Guo^{\overline{2}2}$	China	50	50	$62(40 \sim 75)$	<i>~</i> 75)	NA	NA	NA	NA	03468
Li <sup>28</sup>	China	25	25	$58.05 \pm 10.22$	$56.18 \pm 8.43$	20/5	21/4	0/0/2/14/9	0/1/4/14/6	00
Lin <sup>15</sup>	China	72	72	59.21±	$59.21 \pm 10.05$	60/12	62/10	NA	NA	38
$Ma^{26}$	China	51	51	$55.96 \pm 6.11$	$56.04 \pm 9.27$	NA	NA	NA	NA	0236
Panici et al <sup>23</sup>	Italy	56	56	$47 \pm 21$	$48.5\pm18.8$	NA	NA	0/0/0/24/32	0/0/0/30/26	Θ
Ramirez et al <sup>24</sup>	SU	319	312	$46.0\pm10.6$	$46.1 \pm 11.0$	210/109	214/98	25/287/0/0/0	26/293/0/0/0	89
$Song^{19}$	China	76	76	$62.8\pm10.5$	$59.2 \pm 9.6$	65/11	66/10	NA	NA	0368
$Sun^{16}$	China	45	45	$46.12 \pm 6.84$	$48.51\pm6.82$	NA	NA	NA	NA	000
Wang <sup>21</sup>	China	28	28	$60.44 \pm$	$4 \pm 9.12$	NA	NA	NA	NA	03457
$Zhao^{20}$	China	40	40	$57.15 \pm 8.05$	$58.08 \pm 9.24$	33/7	32/8	0/0/0/21/19	0/0/1/22/17	0368
©duration of s ARH indicates	urgery; ©intraof abdominal radi	perative blo ical hystere	od loss; ∉ ctomy; LF	Oduration of surgery; @intraoperative blood loss; @number of lymph nodes removed; @intraoperative comp ARH indicates abdominal radical hysterectomy; LRH, laparoscopic radical hysterectomy; NA, not available	es removed; @intraope il hysterectomy; NA, 1	Oduration of surgery: @intraoperative blood loss; @number of lymph nodes removed; @intraoperative complications; @postoperative complications; @the time to first passage of flatus; @relapse rate; @survival rate. ARH indicates abdominal radical hysterectomy; LRH, laparoscopic radical hysterectomy; NA, not available.	ive complications; ©th	te time to first passage of flatue	s; Orelapse rate; ®surviva	l rate.




FIGURE 1. Preferred reporting items for systematic reviews and meta-analyses flow diagram of randomized controlled trialselection.

# RESULTS


## **RCT Selection**


A total of 238 literatures were initially detected in the first literature search. After reading the titles and abstracts, 58 papers were included after excluding the literatures that did not meet the inclusion criteria. After reading the full text of the literature, 14 RCTs<sup>15–28</sup> were finally included (Fig. 1). Of the included 14 RCTs, a total of 1700 patients with cervical cancer were involved, 852 patients underwent

LRH treatment, 848 patients underwent ARH treatment. The basic characteristics of the included studies are shown in Table 1.

## Literature Quality Evaluation

Of all the 14 included RCTs, 11 RCTs<sup>15–22,24–26</sup> described specific methods for generating random sequences, and another 3 RCTs did not mention specific randomization methods. Only 6 RCTs reported specific allocation concealment methods. Blinding of participants and personnel and





Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

outcome assessment (detection bias) were not stated in the included RCTs. No loss to follow-up and selective outcomes were reported. The results of the literature quality evaluation are shown in Figures 2 and 3.

# Meta-analysis

## **Duration of Surgery**

Eleven included RCTs<sup>16,18–23,25–28</sup> reported the duration of surgery. Meta-analysis of random effects model showed that there was no significant difference in the duration of surgery between LRH group and ARH group (MD = 27.62; 95% CI, -6.26, 61.49; P = 0.11, Fig. 4A), with evidence of heterogeneity (P < 0.001,  $l^2 = 99\%$ ).

# Intraoperative Blood Loss

Ten included RCTs<sup>16,19–23,25–28</sup> reported the intraoperative blood loss. Meta-analysis of random effects model showed that the intraoperative blood loss in the LRH group was significantly less than that of ARH group (MD = -58.08; 95% CI, -70.91, -45.24; P < 0.001, Fig. 4B), with evidence of heterogeneity (P < 0.001,  $I^2 = 73\%$ ).

# Number of Lymph Nodes Removed

Eight included RCTs<sup>16,18,19,21–23,25,26</sup> reported the number of lymph nodes removed. Meta-analysis of random effects model showed that the number of lymph nodes removed in the LRH group was significantly more than that of ARH group (MD = 3.47; 95% CI, 0.51, 6.43; P = 0.02, Fig. 4C), with evidence of heterogeneity (P < 0.001,  $I^2 = 97\%$ ).

# The Time to First Passage of Flatus

Seven included RCTs<sup>16,19,20,22,25–27</sup> reported the time to first passage of flatus. Meta-analysis of random effects model showed that the time to first passage of flatus in the LRH group was significantly less than that of ARH group (MD=-14.50; 95% CI, -16.55, -12.44; P < 0.001, Fig. 4D), with evidence of heterogeneity (P = 0.003,  $I^2 = 70\%$ ).

## Intraoperative Complications

Three included RCTs<sup>18,21,22</sup> reported the intraoperative complications. Meta-analysis of random effects model showed that there was no significant difference in intraoperative complications between LRH group and ARH group (OR = 1.10; 95% CI, 0.17, 7.32; P = 0.92, Fig. 5A), with evidence of heterogeneity (P = 0.12,  $I^2 = 53\%$ ).

# **Postoperative Complications**

Three included  $RCTs^{18,20,21}$  reported the postoperative complications. Meta-analysis of fixed effects model showed that there was no significant difference in postoperative complications between LRH group and ARH group (OR = 0.78; 95% CI, 0.33, 1.86; P = 0.57, Fig. 5B], with no evidence of heterogeneity (P = 0.21,  $I^2 = 37\%$ ).

#### **Relapse Rate**

Five included RCTs<sup>15,21,24,27,28</sup> reported the relapse rate. The meta-analysis of random effects model showed that there was no significant difference in the relapse rate between LRH group and ARH group (OR = 1.45; 95% CI, 0.56, 3.74; P = 0.44, Fig. 5C), with evidence of heterogeneity (P = 0.07,  $I^2 = 54\%$ ).




FIGURE 3. Risk of bias summary.

#### **Survival Rate**

Six included RCTs<sup>15,19,20,22,24,27</sup> reported the survival rate. The meta-analysis of fixed effects model showed that there was no significant difference in the survival rate between LRH group and ARH group (OR = 0.75; 95% CI, 0.52, 1.08; P = 0.12, Fig. 5D], with evidence of heterogeneity (P = 0.08,  $I^2 = 48\%$ ).

		LRH			ARH			Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Rar	dom, 95% Cl			
Campos 2013	264.38	49.29	16	240.36	26.85	14	8.9%	24.02 [-3.93, 51.97]					
Dai 2016	242.6	73.2	20	189.2	61.3	20	8.2%	53.40 [11.56, 95.24]					
Dong 2018	141.4	15.3	40	238.6	21.4	40	9.4%	-97.20 [-105.35, -89.05]					
Guo 2017	236.8	63.1	50	141.7	24.3	50	9.2%	95.10 [76.36, 113.84]					
Li 2010	202.2	26.5	25	269.8	22.8	25	9.3%	-67.60 [-81.30, -53.90]					
Ma 2018	239.3	66.7	51	156.9	41.5	51	9.1%	82.40 [60.84, 103.96]					
Panici 2006	75	8.4	56	58.6	7.2	56	9.4%	16.40 [13.50, 19.30]		*			
Song 2015	237.5	62.92	76	142.5	25	76	9.2%	95.00 [79.78, 110.22]					
Sun 2022	158.79	19.64	45	120.01	18.56	45	9.4%	38.78 [30.88, 46.68]		-			
Wang 2013	233	78	28	169	42	28	8.7%	64.00 [31.19, 96.81]					
Zhao 2017	203.85	24.86	40	195.48	27.55	40	9.3%	8.37 [-3.13, 19.87]		-			
Total (95% CI)			447			445	100.0%	27.62 [-6.26, 61.49]		-			
Heterogeneity: Tau <sup>2</sup> =	3169.90;	Chi <sup>2</sup> = 1	1115.03	3, df = 10	(P < 0.	00001)	l <sup>2</sup> = 99%		-100 -50	0 50 100			

		LRH		ARH				Mean Difference	Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl		
Dai 2016	356.5	124.5	20	462.3	102.4	20	2.8%	-105.80 [-176.45, -35.15]			
Dong 2018	305.6	32.5	40	380.6	34.3	40	14.5%	-75.00 [-89.64, -60.36]			
Guo 2017	313.5	38.5	50	373.8	32.1	50	14.8%	-60.30 [-74.19, -46.41]			
Li 2010	315.8	29.8	25	396.5	31.5	25	13.6%	-80.70 [-97.70, -63.70]			
Ma 2018	299.8	49.2	51	361.4	60.3	51	11.9%	-61.60 [-82.96, -40.24]			
Panici 2006	100	120	56	110	146	56	4.9%	-10.00 [-59.50, 39.50]			
Song 2015	314	38.47	76	374	32.09	76	15.7%	-60.00 [-71.26, -48.74]	-		
Sun 2022	0	0	45	0	0	45		Not estimable			
Wang 2013	316	62	28	353	66	28	8.0%	-37.00 [-70.54, -3.46]			
Zhao 2017	295.75	35.82	40	325.83	39.21	40	13.8%	-30.08 [-46.54, -13.62]			
Total (95% CI)			431			431	100.0%	-58.08 [-70.91, -45.24]	•		
Heterogeneity: Tau <sup>2</sup> =	240.36; 0	Chi <sup>2</sup> = 29	9.78, df	= 8 (P =	0.0002	;  2 = 7	3%			2	
Test for overall effect:	Z = 8.87	(P < 0.0	0001)						-100 -50 0 50 100 Favours [LRH] Favours [ARH		

		LRH			ARH			Mean Difference		Me	an Differe	nce	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random. 95% CI		IV. F	andom, 9	5% CI	
Campos 2013	19.5	8.41	16	19.43	6.35	14	9.4%	0.07 [-5.23, 5.37]					
Dong 2018	24.5	3.2	40	17.7	2.7	40	13.1%	6.80 [5.50, 8.10]				-	-
Guo 2017	24.2	3.1	50	18.5	2.6	50	13.2%	5.70 [4.58, 6.82]				-	
Ma 2018	28.2	3.9	51	18.8	4.1	51	13.0%	9.40 [7.85, 10.95]					
Panici 2006	30	6.7	56	36	7.2	56	12.2%	-6.00 [-8.58, -3.42]	10				
Song 2015	24	2.97	76	18.8	2.59	76	13.3%	5.20 [4.31, 6.09]					
Sun 2022	12.67	2.22	45	13.51	2.15	45	13.3%	-0.84 [-1.74, 0.06]					
Wang 2013	24	4	28	18	4	28	12.6%	6.00 [3.90, 8.10]					
Total (95% CI)			362			360	100.0%	3.47 [0.51, 6.43]					
Heterogeneity: Tau <sup>2</sup> =	16.95; 0	chi² = :	253.99,	df = 7 (	P < 0.	00001)	l² = 97%			-	_		+
Test for overall effect:	Z = 2.30	(P=0	0.02)						-10	-5 Favours [	0	5	10




FIGURE 4. Forest plots for synthesized outcomes. ARH indicates abdominal radical hysterectomy; CI, confidence interval; LRH, laparoscopic radical hysterectomy. Tradicate hysterectomy.

# **Publication Bias**

As showed in Figures 6 and 7, the dots in the funnel plots for synthesized outcomes were evenly distributed, and the results of Egger regression tests indicated that there was no publication bias in the synthesized outcomes (all P > 0.05).

# Sensitivity Analyses

Sensitivity analyses that assess the impact of single 1 study on the overall risk estimate by removing 1 study in each turn. No significant change of the overall risk estimates by removing any single study was found.

	LRH		ARH			Odds Ratio			Ratio	
Study or Subgroup	Events 7	otal I		otal	Weight	M-H. Random, 95% CI		M-H, Rand	lom. 95% Cl	_
Campos 2013	4	16	0	14	24.0%	10.44 [0.51, 213.52]				
Guo 2017	5	50	11	50	50.1%	0.39 [0.13, 1.23]			T	
Wang 2013	1	28	1	28	26.0%	1.00 [0.06, 16.82]				
Total (95% CI)		94		92	100.0%	1.10 [0.17, 7.32]				
Total events	10		12						· · · · ·	
Heterogeneity: Tau <sup>2</sup> =				= 0.12)	; l <sup>2</sup> = 53%		0.005	0.1	1 10	2
Test for overall effect: 2	<u>z</u> = 0.10 (P	= 0.92)					0.000		Favours [ARH]	80
В			Fores	st plo	t for post	toperative complica	tions			
	LRH	R	AR			Odds Ratio		Odds	Ratio	
Study or Subgroup					Weight	M-H. Fixed. 95% CI			ed. 95% Cl	
Campos 2013	3	16	5	14			-			
Wang 2013	3	28	5	28		이 집에 가지 않는 것이 같이 가지 않는 것이 같이 많이 많이 했다.	-		<u> </u>	
Zhao 2017	5	20 40	2	40						
21120 2017	5	40	2	40	15.5%	2.71 [0.49, 14.90]		85 D 20		
Total (95% CI)		84		82	100.0%	0.78 [0.33, 1.86]				
Total events	11		13				1		1	
Heterogeneity: Chi <sup>2</sup> =				37%		0	.05	0.2	1 5	
Test for overall effect:	: Z = 0.56 (I	$^{3} = 0.5$	7)						Favours [ARH]	
								r aroaio (Erail)	r aroaio (r a a g	
С				Fo	rest plot	for relapse rate				
	LRH		ARH			Odds Ratio		Odds	Ratio	
Study or Subgroup	Events 7	otal	Events	Total	Weight	M-H. Random, 95% CI		M-H, Rand	lom, 95% Cl	
Dai 2016	3	20	2	20	15.8%	1.59 [0.24, 10.70]			•	
Li 2010	0	25	2	25	7.8%	0.18 [0.01, 4.04]				
Lin 2013	19	72	20	72	34.8%	0.93 [0.45, 1.94]			-	
Ramirez 2018	27	319	7	312	32.6%	4.03 [1.73, 9.39]				
Wang 2013	1	28	1	28	9.0%	1.00 [0.06, 16.82]				
Total (95% CI)		464		457	100.0%	1.45 [0.56, 3.74]		-	•	
			32							
Total events	50			- 0 07	12 - 540/		_		<u> </u>	-
Y222 1330		8.66, 0	df = 4 (P :	- 0.07	; 1- = 54%					1
Total events	0.53; Chi <sup>2</sup> =			- 0.07	; 1~ = 54%		0.01	0.1 Favours (LRH)	1 10 Favours (ARH)	
Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2	0.53; Chi <sup>2</sup> =			030			0.01		Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> =	0.53; Chi² = Z = 0.77 (P	= 0.44)	)	Fo		for survival rate	0.01	Favours [LRH]	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2	0.53; Chi² = Z = 0.77 (P LRH	= 0.44)	ARH	Fo	rest plot	for survival rate Odds Ratio	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = Test for overall effect: 2 D <u>Study or Subgroup</u>	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH Events	= 0.44) Total	ARH	Fo I Total	rest plot Weight	for survival rate Odds Ratio M-H. Fixed, 95% CI	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D <u>Study or Subgroup</u> Dai 2016	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17	= 0.44) <u>Total</u> 20	ARF Events 18	Fo I <u>Total</u> 20	vrest plot <u>Weight</u> 4.0%	for survival rate Odds Ratio M-H. Fixed. 95% CI 0.63 [0.09, 4.24]	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D <u>Study or Subgroup</u> Dai 2016 Guo 2017	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17 24	= 0.44) <u>Total</u> 20 50	ARI- Events 18 22	Fo I <u>Total</u> 20 50	Weight 4.0% 16.9%	for survival rate Odds Ratio M-H, Fixed, 95% CI 0.63 [0.09, 4.24] 1.17 [0.53, 2.58]	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D <u>Study or Subgroup</u> Dai 2016 Guo 2017 Lin 2013	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17 24 65	= 0.44) <u>Total</u> 20 50 72	ARI- Events 18 22 65	Fo I Total 20 50 72	Weight 4.0% 16.9% 9.4%	for survival rate Odds Ratio M-H, Fixed, 95% CI 0.63 [0.09, 4.24] 1.17 [0.53, 2.58] 1.00 [0.33, 3.01]	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D <u>Study or Subgroup</u> Dai 2016 Guo 2017 Lin 2013 Ramirez 2018	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17 24 65 300	= 0.44) <u>Total</u> 20 50 72 319	ARH Events 18 22 65 310	Fo I Total 20 50 72 312	Weight 4.0% 16.9% 9.4% 27.6%	for survival rate Odds Ratio M-H. Fixed. 95% CI 0.63 [0.09, 4.24] 1.17 [0.53, 2.58] 1.00 [0.33, 3.01] 0.10 [0.02, 0.44]	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D <u>Study or Subgroup</u> Dai 2016 Guo 2017 Lin 2013 Ramirez 2018 Song 2015	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17 24 65 300 35	= 0.44) <u>Total</u> 20 50 72 319 76	ARI- Events 18 22 65 310 37	Fo I Total 20 50 72 312 76	Weight 4.0% 16.9% 9.4% 27.6% 29.6%	for survival rate Odds Ratio M-H, Fixed, 95% CI 0.63 [0.09, 4.24] 1.17 [0.53, 2.58] 1.00 [0.33, 3.01] 0.10 [0.02, 0.44] 0.90 [0.48, 1.70]	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D <u>Study or Subgroup</u> Dai 2016 Guo 2017 Lin 2013 Ramirez 2018	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17 24 65 300	= 0.44) <u>Total</u> 20 50 72 319	ARH Events 18 22 65 310	Fo I Total 20 50 72 312	Weight 4.0% 16.9% 9.4% 27.6% 29.6%	for survival rate Odds Ratio M-H. Fixed. 95% CI 0.63 [0.09, 4.24] 1.17 [0.53, 2.58] 1.00 [0.33, 3.01] 0.10 [0.02, 0.44]	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D <u>Study or Subgroup</u> Dai 2016 Guo 2017 Lin 2013 Ramirez 2018 Song 2015	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17 24 65 300 35	= 0.44) <u>Total</u> 20 50 72 319 76	ARI- Events 18 22 65 310 37	Fo I 20 50 72 312 76 40	Weight 4.0% 16.9% 9.4% 27.6% 29.6%	for survival rate Odds Ratio M-H, Fixed, 95% CI 0.63 [0.09, 4.24] 1.17 [0.53, 2.58] 1.00 [0.33, 3.01] 0.10 [0.02, 0.44] 0.90 [0.48, 1.70]	0.01	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D Study or Subgroup Dai 2016 Guo 2017 Lin 2013 Ramirez 2018 Song 2015 Zhao 2017	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17 24 65 300 35	= 0.44) <u>Total</u> 20 50 72 319 76 40	ARI- Events 18 22 65 310 37	Fo I 20 50 72 312 76 40	Weight 4.0% 16.9% 9.4% 27.6% 29.6% 12.5%	for survival rate Odds Ratio M-H, Fixed, 95% Cl 0.63 [0.09, 4.24] 1.17 [0.53, 2.58] 1.00 [0.33, 3.01] 0.10 [0.02, 0.44] 0.90 [0.48, 1.70] 1.12 [0.44, 2.83]	•	Favours [LRH] Odds	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D Study or Subgroup Dai 2016 Guo 2017 Lin 2013 Ramirez 2018 Song 2015 Zhao 2017 Total (95% CI)	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH <u>Events</u> 17 24 65 300 35 27 468	= 0.44) <u>Total</u> 20 50 72 319 76 40 577	ARH Events 18 22 65 310 37 26 478	Fo Total 20 50 72 312 76 40 570	Weight 4.0% 16.9% 9.4% 27.6% 29.6% 12.5%	for survival rate Odds Ratio M-H, Fixed, 95% Cl 0.63 [0.09, 4.24] 1.17 [0.53, 2.58] 1.00 [0.33, 3.01] 0.10 [0.02, 0.44] 0.90 [0.48, 1.70] 1.12 [0.44, 2.83]	•	Favours [LRH]	Favours [ARH]	
Total events Heterogeneity: Tau <sup>2</sup> = 1 Test for overall effect: 2 D <u>Study or Subgroup</u> Dai 2016 Guo 2017 Lin 2013 Ramirez 2018 Song 2015 Zhao 2017 Total (95% CI) Total events	0.53; Chi <sup>2</sup> = Z = 0.77 (P LRH Events 17 24 65 300 35 27 468 9.68, df = 5	= 0.44) <u>Total</u> 20 50 72 319 76 40 577 5 (P = 0	ARH Events 18 22 65 310 37 26 478 0.08); I <sup>2</sup> =	Fo Total 20 50 72 312 76 40 570	Weight 4.0% 16.9% 9.4% 27.6% 29.6% 12.5%	for survival rate Odds Ratio M-H, Fixed, 95% Cl 0.63 [0.09, 4.24] 1.17 [0.53, 2.58] 1.00 [0.33, 3.01] 0.10 [0.02, 0.44] 0.90 [0.48, 1.70] 1.12 [0.44, 2.83]	0.01	Favours [LRH]	Favours [ARH]	2

# DISCUSSIONS

The treatment of cervical cancer should be based on the patient's age, general condition, tumor stage, histologic type, lymph node metastasis, and fertility requirements to formulate the best treatment plan.<sup>29,30</sup> For the diagnosis and treatment of cervical cancer, not only we must follow the basic principles of diagnosis and treatment guidelines, but also pay attention to individualized treatment, so the choice of specific treatment plan often requires the comprehensive judgment of clinicians.<sup>31</sup> The results of clinical studies<sup>32–34</sup> so far have shown that for

patients with early stage of cervical cancer FIGO clinical stage compared with radiotherapy alone, surgical treatment has the advantages of reducing the mortality rate of cervical cancer and the probability of tumor recurrence, and improving the quality of life of patients after surgery. At the same time, the possibility of permanent damage to ovarian function and other normal organs around the tumor by radiation therapy should be considered.<sup>35</sup> Therefore, for patients with early-stage cervical cancer, surgery is still the first choice for treatment. This meta-analysis has included 14 RCTs comparing ARH and LRH in the




FIGURE 6. Funnel plots for synthesized outcomes. MD indicates mean difference; OD, odd ratio.

treatment of cervical cancer. The results have showed that compared with the ARH, the LRH in the treatment of early cervical cancer can reduce the intraoperative blood loss, significantly increase the number of lymph nodes removed, and shorten the time to first passage of flatus. There are no significant differences between the ARH and LRH in terms of duration of surgery, intraoperative complications, postoperative complications, postoperative relapse rate, and survival rate.

We have not found the difference in the duration of surgery between ARH and LRH. On the one hand, the laparoscopic surgery is a new development technology, and the publication time of the included studies in this meta-analysis is different. In earlier studies, the laparoscopic surgery was carried out for a short period of time. ARH is a traditional operation, the surgeon may have higher technical level and richer surgical experience.<sup>36</sup> On the other hand, the "learning curve" of the surgeon also affects the duration of surgery.<sup>37–39</sup> As none of the included studies reported the surgeon's proficiency in LRH and the number of previous surgeries, the learning curve of the surgeons also contributed to the statistical heterogeneity among the included studies. Finally, none of the included studies have reported whether the patients had a history of multiple operations in the lower abdomen, which may cause adhesions between the pelvic and abdominal organs and tissues, leading to longer duration of surgery.

The intraoperative blood loss of LRH is less than that of ARH, and the difference was statistically significant. LRH has a small incision, whereas ARH has a larger incision. The process

of entering the abdominal cavity through the skin layer by layer damages more blood vessels and increases the bleeding of the incision.40 When laparoscopic ultrasonic scalpel is used for tissue separation during surgery, it can not only cut tissue but also stop bleeding in a timely and effective manner, reducing unnecessary bleeding.41,42 Because of the magnifying effect of laparoscopic equipment, it is easier and clearer for the operator to identify important tissue structures such as blood vessels and nerves and the local anatomical relationship between them during surgical operations.43-45 When the laparoscopic eyepiece is close to the observation target, the surgical details can be observed for better and finer operation, and the bleedingprone tissue can be effectively and preventively avoided. When the laparoscopic eyepiece is retreated, the surgical field of view can be expanded, and the operator's awareness of the operation can be improved. The overall grasp of the visual field avoids the omission of small active bleeding foci in the surgical field of view, and can effectively stop bleeding in time, thereby significantly reducing the amount of bleeding on the surgical wound and avoiding the occurrence of major bleeding.<sup>46–48</sup>

The results of this study have showed that the time of the time to the first passage of flatus in the LRH is earlier than that of ARH. The possible reason for the difference may be that laparoscopic surgery avoids the touch of the abdominal retractor, gauze and operator's gloves on the intestine, and the less intestinal tract manipulations in the LRH reduce irritation to the patient's gastrointestinal tract. In addition, laparoscopic surgery is performed in a relatively closed abdominal cavity,




FIGURE 7. Funnel plots for synthesized outcomes. OD indicates odd ratio.

and the pelvic and abdominal organs do not need to be exposed for a long time, and the intestinal tract will not be dry and cold, so that the patient's gastrointestinal motility function can be quickly recovered after surgery.<sup>49–51</sup>

There are no significant differences in recurrence and survival between LRH and ARH. A long-term follow-up study<sup>52</sup> has found that the 5-year survival rate after LRH was basically the same as that of laparotomy. In a retrospective case-control study,<sup>53</sup> 2 groups of cervical cancer patients with different surgical procedures were followed up for 5 years. The results showed that compared with laparoscopic surgery, the 5-year overall survival rates were 95.2% and 96.4%, respectively, the 5-year recurrence-free survival rates were 92.8% and 94.4%, and the 5-year tumor-specific survival rates were 89.6% and 90.7%, respectively. In recent years, some researchers<sup>54-56</sup> have compared the 5-year overall survival rate and 5-year disease-free survival rate of laparoscopic surgery and traditional laparotomy in the treatment of cervical cancer, and have found that there is no significant difference between the 2 groups. We have evaluated the data from English versus Chinese reports, there is a difference in the survival rate between the English versus Chinese reports. Heretofore, the predominance of English data suggests an adverse survival rate associated with a minimally invasive approach. For patients with cervical cancer, whether different surgical methods will improve their postoperative survival rate and which method is more advantageous, there is still no clear conclusion. Therefore,

long-term follow-up results of multiple large-sample RCTs are still needed to confirm and evaluate the effect of LRH and ARH.

There are certain limitations in this study that must be considered. First, because surgery cannot be blinded, this may increase the measurement and performance bias of the study and increase the clinical heterogeneity among included RCTs. Second, some of the measurement indicators in this study were subject to the surgeon's learning curve and clinical experience, and none of the included studies reported whether the surgeons were proficient in LRH and the number of previous surgeries. Third, we included patients not only limited to early stage, we tried to conduct subgroup analysis based on the disease stage, yet the data were limited for subgroup analysis. In addition, most of the included studies had small sample sizes, which may affect the internal validity of the results. It is recommended that randomization methods, allocation concealment, and blinding design should be reported in detail in future clinical trials to reduce selection bias and measurement bias.

# CONCLUSIONS

In conclusion, the results of this meta-analysis have found that LRH is beneficial to reduce the intraoperative blood loss, shorten the recovery time of postoperative gastrointestinal function, and increase the number of lymph nodes removed in patients with cervical cancer compared with ARH. Future research should be based on the patients' safety and quality of life, focusing on postoperative overall survival time, tumor-free survival time, and quality of life of patients with cervical cancer. It is suggested that more RCTs should be carried out on the efficacy of LRH and ARH on postoperative quality of life and other outcomes with larger sample size and longer follow-up.

## REFERENCES

- Dillon J, Chen L, Melamed A, et al. Patterns of cervical cancer screening among Medicaid beneficiaries. BJOG. 2022;129:1104–1111.
- Bruggmann D, Quinkert-Schmolke K, Jaque JM, et al. Global cervical cancer research: a scientometric density equalizing mapping and socioeconomic analysis. *PLoS One*. 2022;17:e0261503.
- Zhao S, Huang L, Basu P, et al. Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries. *Cancer Lett.* 2022;525:22–32.
- Torres-Roman JS, Ronceros-Cardenas L, Valcarcel B, et al. Cervical cancer mortality among young women in Latin America and the Caribbean: trend analysis from 1997 to 2030. *BMC Public Health.* 2022;22:113.
- Daojuan L, Jin S, Jing J. Epidemiological trends of cervical cancer. *Chin J Cancer*. 2021;43:5–8.
- Xihe Y, Jingru Z, Hairui J. Analysis of the disease burden of cervical cancer and breast cancer among Chinese women from 1990 to 2019. *Chinese J Public Health*. 2022;38:534–538.
- Caird H, Simkin J, Smith L, et al. The path to eliminating cervical cancer in Canada: past, present and future directions. *Curr Oncol.* 2022;29:1117–1122.
- Saitoh E, Saika K, Morisada T, et al. Status of cervical cancer screening among adolescents and young adults (AYA) in Japan. *Int J Clin Oncol.* 2022;27:473–480.
- Lichter KE, Levinson K, Hammer A, et al. Understanding cervical cancer after the age of routine screening: characteristics of cases, treatment, and survival in the United States. *Gynecol Oncol.* 2022;165:67–74.
- Yang L, Yang P, Li D, et al. Comparison of safety and efficacy of laparoscopic versus abdominal radical hysterectomy in the treatment of patients with stage I a2-II b cervical cancer. *Zhonghua Fu Chan Ke Za Zhi.* 2015;50:915–922.
- 11. Wenzel HHB, Smolders RGV, Beltman JJ, et al. Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review. *Eur J Cancer*. 2020;133:14–21.
- Zhang M, Dai W, Si Y, et al. Comparison of minimally invasive versus abdominal radical hysterectomy for early-stage cervical cancer: an updated meta-analysis. *Front Oncol.* 2021;11:762921.
- 13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. 2009;339:b2700.
- Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.
- Lin B. Efficacy and quality of life of laparoscopic and open surgery in patients with early cervical cancer. *Chinese J Endoscopy*. 2013;19:462–465.
- Sun B, Yahong L, Ning W. The efficacy and safety of laparoscopic radical hysterectomy and open radical hysterectomy in the treatment of early cervical cancer. *Guizhou Med.* 2022;46:2–4.
- Campos LS, Limberger LF, Stein AT, et al. Survival after laparoscopic versus abdominal radical hysterectomy in early cervical cancer: a randomized controlled trial. *Asian Pac J Cancer Prev.* 2021;22:93–97.
- Campos LS, Limberger LF, Stein AT, et al. Postoperative pain and perioperative outcomes after laparoscopic radical hysterectomy and abdominal radical hysterectomy in patients with early cervical cancer: a randomised controlled trial. *Trials*. 2013;14:293.
- Song F, Wenjie L, Lingyu L. Comparison of laparoscopic surgery and laparotomy in the treatment of early cervical cancer and postoperative quality of life of patients. *J Pract Cancer*. 2015;30:371–373.

- Zhao H. Laparoscopic and open radical resection for cervical cancer combined with para-aortic lymph node dissection in the treatment of early cervical cancer. *Contemp Med.* 2017;23:90–92.
- Wang J. Clinical comparison between laparoscopic surgery and laparotomy in the treatment of early cervical cancer. *Chinese Rura Med.* 2013;20:22–23.
- Guo L. Comparison of the clinical effect of laparoscopic surgery and open surgery in the treatment of early cervical cancer. *Chin Pract Med.* 2017;12:40–41.
- Panici PB, Plotti F, Zullo MA, et al. Pelvic lymphadenectomy for cervical carcinoma: laparotomy extraperitoneal, transperitoneal or laparoscopic approach? A randomized study. *Gynecol Oncol.* 2006;103:859–864.
- Ramirez PT, Frumovitz M, Pareja R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. *N Engl J Med.* 2018;379:1895–1904.
- Dong R, Hong P, Jinjin Y. Comparison of clinical effects between laparoscopic and laparotomy in the treatment of early cervical cancer. J Pract Gynecol Endocrinol. 2018;5:47–50.
- Ma X, Yan H, Zeying C. Comparison of curative effect between laparoscopic surgery and open surgery in the treatment of early cervical cancer. *Chinese Primary Med.* 2018;25:2521–2524.
- Dai Y. The effect of laparoscopic extensive hysterectomy in the treatment of early cervical cancer and its influence on the prognosis of patients. CHN Contemp Med. 2016;23:100–102.
- Li Y. Comparison of the effects of different surgical methods in the early treatment of cervical cancer. *Appl Mod Med China*. 2010;4:83–84.
- Yu Y, Deng T, Gu S. Minimally invasive surgery and abdominal radical hysterectomy in patients with early-stage cervical cancer: a meta-analysis. *Int J Gynaecol Obstet*. 2022;157:255–264.
- Chen B, Ji M, Li P, et al. Comparison between robot-assisted radical hysterectomy and abdominal radical hysterectomy for cervical cancer: a multicentre retrospective study. *Gynecol Oncol.* 2020;157:429–436.
- Chen C, Guo J, Liu P, et al. Comparison of survival outcomes between laparoscopic surgery and abdominal surgery for radical hysterectomy as primary treatment in patients with stage IB2/IIA2 cervical cancer. J Obstet Gynaecol Res. 2021;47:1516–1526.
- 32. Li P, Chen L, Ni Y, et al. Comparison between laparoscopic and abdominal radical hysterectomy for stage IB1 and tumor size <2 cm cervical cancer with visible or invisible tumors: a multicentre retrospective study. J Gynecol Oncol. 2021;32:e17.
- 33. Kim SI, Lee J, Hong J, et al. Comparison of abdominal and minimally invasive radical hysterectomy in patients with early stage cervical cancer. *Int J Med Sci.* 2021;18:1312–1317.
- Wang W, Li L, Wu M, et al. Laparoscopic vs. abdominal radical hysterectomy for locally advanced cervical cancer. *Front Oncol.* 2019;9:1331.
- Nitecki R, Ramirez PT, Frumovitz M, et al. Survival after minimally invasive vs open radical hysterectomy for early-stage cervical cancer: a systematic review and meta-analysis. *JAMA Oncol.* 2020;6:1019–1027.
- 36. Kim SI, Cho JH, Seol A, et al. Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer. *Gynecol Oncol.* 2019;153:3–12.
- Kim S, Min KJ, Lee S, et al. Learning curve could affect oncologic outcome of minimally invasive radical hysterectomy for cervical cancer. *Asian J Surg.* 2021;44:174–180.
- Baeten I, Hoogendam JP, Schreuder H, et al. The influence of learning curve of robot-assisted laparoscopy on oncological outcomes in early-stage cervical cancer: an observational cohort study. *BJOG*. 2021;128:563–571.
- Li LY, Wen LY, Park SH, et al. Impact of the learning curve on the survival of abdominal or minimally invasive radical hysterectomy for early-stage cervical cancer. *Cancer Res Treat.* 2021;53:243–251.
- Ohta T, Nagase S, Okui Y, et al. Surveillance of radical hysterectomy for early-stage cervical cancer in the early experienced period of minimally invasive surgery in Japan. *Int J Clin Oncol.* 2021;26:2318–2330.
- Guo C, Tang X, Meng Y, et al. Effect of the surgical approach on survival outcomes in patients undergoing radical hysterectomy for

cervical cancer: a real-world multicenter study of a large Chinese cohort from 2006 to 2017. *Cancer Med.* 2020;9:5908–5921.

- Levine MD, Brown J, Crane EK, et al. Outcomes of minimally invasive versus open radical hysterectomy for early stage cervical cancer incorporating 2018 FIGO staging. J Minim Invasive Gynecol. 2021;28:824–828.
- Eoh KJ, Lee JY, Nam EJ, et al. The institutional learning curve is associated with survival outcomes of robotic radical hysterectomy for early-stage cervical cancer-a retrospective study. *BMC Cancer*. 2020;20:152.
- 44. Chen X, Liang W, Duan H, et al. Discussion on the treatment strategy for stage A1 crvical cancer (FIGO 2018). *Front Oncol.* 2022;12:800049.
- Baiocchi G, Ribeiro R, Dos Reis R, et al. Open versus minimally invasive radical hysterectomy in cervical cancer: the CIRCOL Group study. *Ann Surg Oncol.* 2022;29:1151–1160.
- 46. Shi D, Liang Z, Zhang C, et al. The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy/chemoradiotherapy: a meta-analysis. *BMC Cancer*. 2018;18:308.
- 47. Cheng J, Liu B, Wang B, et al. Effectiveness comparisons of various therapies for FIGO stage IB2/IIA2 cervical cancer: a Bayesian network meta-analysis. *BMC Cancer*. 2021;21:1078.
- Chen C, Duan H, Zhang W, et al. Comparison of survival outcomes with or without Para-aortic lymphadenectomy in surgical patients with stage IB1-IIA2 cervical cancer in China from 2004 to 2016. *BMC Cancer*. 2021;21:1091.

- 49. Liu Z, Li X, Tian S, et al. Superiority of robotic surgery for cervical cancer in comparison with traditional approaches: a systematic review and meta-analysis. *Int J Surg.* 2017;40:145–154.
- Zullo F, Palomba S, Russo T, et al. A prospective randomized comparison between laparoscopic and laparotomic approaches in women with early stage endometrial cancer: a focus on the quality of life. *Am J Obstet Gynecol.* 2005;193:1344–1352.
- Januszek SM, Wita-Popow B, Kluz M, et al. Risk factors for surgical treatment of endometrial cancer using traditional and laparoscopic methods. J Clin Med. 2021;10:429.
- 52. Lee EJ, Kang H, Kim DH. A comparative study of laparoscopic radical hysterectomy with radical abdominal hysterectomy for early-stage cervical cancer: a long-term follow-up study. *Eur J Obstet Gynecol Reprod Biol.* 2011;156:83–86.
- Nam JH, Park JY, Kim DY, et al. Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study. *Ann Oncol.* 2012;23:903–911.
- Bogani G, Cromi A, Uccella S, et al. Laparoscopic versus open abdominal management of cervical cancer: long-term results from a propensity-matched analysis. J Minim Invasive Gynecol. 2014; 21:857–862.
- Park JY, Kim DY, Kim JH, et al. Laparoscopic versus open radical hysterectomy for elderly patients with early-stage cervical cancer. *Am J Obstet Gynecol*. 2012;207:195. e191–e198.
- Park JY, Kim DY, Kim JH, et al. Laparoscopic compared with open radical hysterectomy in obese women with early-stage cervical cancer. *Obstet Gynecol.* 2012;119:1201–1209.